Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Therapeutics

• Publication date

  2013-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clinthera.2013.03.021PMID 23642290
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Longitudinal association between medication adherence and glycaemic control in Type 2 diabetes

  2013cited by this paper
• Cost-related Nonadherence by Medication Type Among Medicare Part D Beneficiaries With Diabetes

  2013cited by this paper
• Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study

  2013cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• Medication Adherence in Type 2 Diabetes: The ENTRED Study 2007, a French Population-Based Study

  2012cited by this paper
• Appointment and medication non-adherence is associated with increased mortality in insulin-treated type 2 diabetes

  2012cited by this paper
• Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

  2012cited by this paper
• Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes

  2012cited by this paper
• The economic rationale for adherence in the treatment of type 2 diabetes mellitus.

  2012cited by this paper
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2012cited by this paper
• Standards of Medical Care in Diabetes—2013

  2012cited by this paper
• Medication Nonadherence in Diabetes

  2012cited by this paper
• Exenatide

  2012cited by this paper
• A retrospective database analysis of neuropathic pain and oral antidiabetic medication use and adherence among Texas adults with type 2 diabetes enrolled in Medicaid.

  2012cited by this paper
• Recommendations for improving adherence to type 2 diabetes mellitus therapy--focus on optimizing oral and non-insulin therapies.

  2012cited by this paper
• Regional, Geographic, and Ethnic Differences in Medication Adherence among Adults with Type 2 Diabetes

  2011cited by this paper
• A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States

  2011cited by this paper
• Diagnosis and Classification of Diabetes Mellitus

  2011cited by this paper
• Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

  2011cited by this paper
• One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

  2011cited by this paper
• Standards of Medical Care in Diabetes—2012

  2011cited by this paper
• Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

  2010cited by this paper
• Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.

  2010cited by this paper
• Article: Treatment

  2010cited by this paper
• Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230))

  2010cited by this paper
• Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin

  2010cited by this paper
• Global estimates of the prevalence of diabetes for 2010 and 2030.

  2010cited by this paper
• Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents

  2010cited by this paper
• Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.

  2010cited by this paper
• Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

  2009cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009cited by this paper
• Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

  2009cited by this paper
• Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

  2009cited by this paper
• Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

  2009cited by this paper
• Good and poor adherence: optimal cut-point for adherence measures using administrative claims data

  2009cited by this paper
• Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes.

  2009cited by this paper
• The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies

  2009cited by this paper
• How Does Treatment Satisfaction Work?

  2009cited by this paper
• Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

  2008cited by this paper
• Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

  2008cited by this paper
• Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

  2008cited by this paper
• DIABETICMedicine Blackwell Publishing Ltd Original Article: Complications DOI: 10.1111/j.1464-5491.2009.02667.x Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor

  2008cited by this paper
• Reducing Cardiovascular Complications of Type 2 Diabetes by Targeting Multiple Risk Factors

  2008cited by this paper
• Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

  2008cited by this paper
• Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real‐Life Effectiveness and Care Patterns of Diabetes Management (RECAP‐DM) study

  2008cited by this paper
• Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study.

  2007cited by this paper
• Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.

  2007cited by this paper
• Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).

  2007cited by this paper
• Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review.

  2006cited by this paper
• Estimating medication persistency using administrative claims data.

  2005cited by this paper
• Suboptimal medication adherence in Parkinson's disease

  2005cited by this paper
• Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance.

  2005cited by this paper
• Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost

  2005cited by this paper
• A systematic review of adherence with medications for diabetes.

  2004cited by this paper
• A Systematic Review of Adherence With Medications for Diabetes

  2004cited by this paper
• Sulfonylurea Pharmacotherapy Regimen Adherence in a Medicaid Population: Influence of Age, Gender, and Race

  1999cited by this paper
• Validation of pharmacy records in drug exposure assessment.

  1997cited by this paper

• Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes

  2026cites this paper
• Real-World Evidence of Long-Term Dulaglutide Use: Sustained Glycemic and Weight Improvements Beyond Three Years.

  2025cites this paper
• Press-Through Packaging versus Bold and Slim Bottle-Type Containers: A Comparative Evaluation of Drug Packaging Usability in Patients with Rheumatic Diseases

  2025cites this paper
• A global systematic overview of socioeconomic factors associated with antidiabetic medication adherence in individuals with type 2 diabetes

  2023cites this paper
• Gender-Related Factors in Medication Adherence for Metabolic and Cardiovascular Health

  2023cites this paper
• Selective Androgen Receptor Modulator Microparticle Formulation Reverses Muscle Hyperalgesia in Mouse Model of Widespread Muscle Pain

  2022cites this paper
• Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK

  2022cites this paper
• Selective androgen receptor modulator microparticle formulation reverses muscle hyperalgesia in a mouse model of widespread muscle pain.

  2022cites this paper
• A Study on Weight Loss Cause as per the Side Effect of Liraglutide

  2022cites this paper
• Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review

  2021influential citation
• Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States

  2020cites this paper
• Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence

  2019cites this paper
• Medication regimen complexity and its impact on medication adherence and glycemic control among patients with type 2 diabetes mellitus in an Ethiopian general hospital

  2019cites this paper
• L’aderenza al trattamento nel diabete e nell’obesità: quanto conta il genere?

  2019cites this paper
• Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement

  2018cites this paper
• Promjene metabolizma željeza u mozgu i jetri mužjaka Sprague Dawley štakora izloženih masnoj i slatkoj hrani

  2018cites this paper
• Diabète de type 2 : observance thérapeutique aux nouveaux antidiabétiques

  2018cites this paper
• Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement

  2018cites this paper
• Safety of once-weekly glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes

  2018cites this paper
• Bariatric Surgery or Intensive Medical Therapy for Diabetes after 5 Years.

  2017cites this paper
• Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.

  2017cites this paper
• Bariatric Surgery or Intensive Medical Therapy for Diabetes after 5 Years.

  2017cites this paper
• Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide

  2017influential citation
• Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population

  2017cites this paper
• Medication adherence and improved outcomes among patients with type 2 diabetes.

  2017cites this paper
• Bariatric Surgery or Intensive Medical Therapy for Diabetes after 5 Years.

  2017cites this paper
• Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes.

  2016cites this paper
• Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.

  2016cites this paper
• Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database

  2016cites this paper
• Prescription Factors Associated with Medication Non-adherence in Japan Assessed from Leftover Drugs in the SETSUYAKU-BAG Campaign: Focus on Oral Antidiabetic Drugs

  2016influential citation
• Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany

  2016cites this paper
• Predicting Noninsulin Antidiabetic Drug Adherence Using a Theoretical Framework Based on the Theory of Planned Behavior in Adults With Type 2 Diabetes

  2016cites this paper
• Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France

  2016cites this paper
• EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM.

  2016cites this paper
• Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States

  2016cites this paper
• A Systematic Review of Insulin Adherence Measures in Patients with Diabetes

  2016cites this paper
• Adhésion au traitement antidiabétique oral chez les adultes atteints de diabète de type 2 : déterminants et interventions visant à l'améliorer

  2016cites this paper
• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress

  2016cites this paper
• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress

  2016cites this paper
• A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes

  2015cites this paper
• Geographic Variation in Antidiabetic Agent Adherence and Glycemic Control Among Patients with Type 2 Diabetes

  2015cites this paper
• After 10 Years of Clinical Trials with Liraglutide in Diabetes, What do we Know About its Effects on Clinical Cardiovascular Outcomes?

  2015cites this paper
• Impact of Medication Adherence and Persistence on Clinical and Economic Outcomes in Patients with Type 2 Diabetes Treated with Liraglutide: A Retrospective Cohort Study

  2015cites this paper
• Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis

  2015cites this paper
• Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin

  2015cites this paper
• Brief review A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes

  2015cites this paper
• Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice

  2015cites this paper
• Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice.

  2015cites this paper
• Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes.

  2014cites this paper
• Retrospective Analysis of Long-Term Adherence to and Persistence with DPP-4 Inhibitors in US Adults with Type 2 Diabetes Mellitus

  2014cites this paper
• Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States

  2014cites this paper
• Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin

  2013cites this paper
• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress

  2011cites this paper